Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11805474 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL560955 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL4530110 | 0.91 | TSHR (0.37) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL14678840 | 0.88 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1101582 | 0.88 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL5665833 | 0.87 | — | — | |
| SCHEMBL39090 | 0.84 | TSHR (0.37) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1053504 | 0.84 | TSHR (0.37) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL12191378 | 0.84 | TSHR (0.41) | ALDH1A1TSHR | |
| SCHEMBL11781892 | 0.83 | SMN1; SMN2 (0.48) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244954-A1 | QUANTUM DOT LIGAND, QUANTUM DOT-LIGAND SYSTEM AND QUANTUM DOT MATERIAL | Beijing Boe Technology Development Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240244954-A1 | QUANTUM DOT LIGAND, QUANTUM DOT-LIGAND SYSTEM AND QUANTUM DOT MATERIAL | CDYL, CD2, CDYL2 | ALDH1A1 2512/4885TSHR 1287/4885SMN1; SMN2 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.